The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome
To report the use of recombinant activated factor VII (rFVIIa) in controlling life-threatening bleeding episodes in patients with grades III and IV Dengue Hemorrhagic Fever (DHF), also known as Dengue Shock Syndrome. Fifteen patients (seven boys, eight girls), whose median age was 8 years, were enro...
Saved in:
Main Authors: | Chuansumrit A., Tangnararatchakit K., Lektakul Y., Pongthanapisith V., Nimjaroenniyom N., Thanarattanakorn P., Wongchanchailert M., Komwilaisak P. |
---|---|
Format: | Article |
Language: | English |
Published: |
2014
|
Online Access: | http://www.scopus.com/inward/record.url?eid=2-s2.0-2942615463&partnerID=40&md5=298770d06fed53822f12b8e523feb02a http://cmuir.cmu.ac.th/handle/6653943832/4134 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Language: | English |
Similar Items
-
The use of recombinant activated factor VII for controlling life-threatening bleeding in Dengue Shock Syndrome
by: Ampaiwan Chuansumrit, et al.
Published: (2018) -
Silica-associated connective tissue syndrome with acquired hemophilia (Factor VIII inhibitor), presenting with life-threatening bleed
by: Santosa, A., et al.
Published: (2016) -
Cardiovascular change in children with dengue shock syndrome
by: Anant Khositseth, et al.
Published: (2018) -
Recombinant activated factor VII in children with acute bleeding resulting from liver failure and disseminated intravascular coagulation
by: Ampaiwan Chuansumrit, et al.
Published: (2018) -
Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: A randomized, double-blind, placebo-controlled study
by: Ampaiwan Chuansumrit, et al.
Published: (2018)